Is Buying Aptevo Therapeutics Inc (NASDAQ:APVO), Having Lower Short Interest a Winning Strategy?

March 18, 2018 - By Peter Erickson

 Is Buying Aptevo Therapeutics Inc (NASDAQ:APVO), Having Lower Short Interest a Winning Strategy?

The stock of Aptevo Therapeutics Inc (NASDAQ:APVO) registered a decrease of 1.76% in short interest. APVO’s total short interest was 285,000 shares in March as published by FINRA. Its down 1.76% from 290,100 shares, reported previously. With 281,700 shares average volume, it will take short sellers 1 days to cover their APVO’s short positions. The short interest to Aptevo Therapeutics Inc’s float is 1.86%.

The stock decreased 2.31% or $0.07 during the last trading session, reaching $2.96. About 140,778 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The company has market cap of $63.47 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. It has a 9.05 P/E ratio. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.